Etiology of Acute Otitis Media and Characterization of Pneumococcal Isolates After Introduction of 13-Valent Pneumococcal Conjugate Vaccine in Japanese Children

被引:38
|
作者
Ubukata, Kimiko [1 ]
Morozumi, Miyuki [1 ]
Sakuma, Megumi [1 ]
Takata, Misako [1 ]
Mokuno, Eriko [2 ]
Tajima, Takeshi [3 ]
Iwata, Satoshi [1 ,4 ]
机构
[1] Keio Univ, Sch Med, Dept Infect Dis, Tokyo, Japan
[2] Hakujikai Mem Hosp, Dept Otorhinolaryngol, Tokyo, Japan
[3] Hakujikai Mem Hosp, Dept Pediat, Tokyo, Japan
[4] Natl Canc Ctr, Dept Infect Dis, Tokyo, Japan
关键词
acute otitis media; causative pathogen; Streptococcus pneumoniae; pneumococcal conjugate vaccine; serotype; multilocus sequence typing; COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; UNITED-STATES; PEDIATRIC-PATIENTS; MIDDLE-EAR; ANTIBIOTIC SUSCEPTIBILITY; ANTIMICROBIAL RESISTANCE; PCV7/PCV13; INTRODUCTION; SEROTYPE DISTRIBUTION; TEBIPENEM-PIVOXIL;
D O I
10.1097/INF.0000000000001956
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Acute otitis media is a leading cause of childhood morbidity and antibiotic prescriptions. We examined etiologic changes in acute otitis media after introduction of 13-valent pneumococcal conjugate vaccine as routine immunization for Japanese children in 2014. Serotypes, resistance genotypes, antibiotic susceptibilities and multilocus sequence typing of pneumococcal isolates were also characterized. Methods: Otolaryngologists prospectively collected middle ear fluid from 582 children by tympanocentesis or sampling through a spontaneously ruptured tympanic membrane between June 2016 and January 2017. Causative pathogens were identified by bacterial culture and real-time polymerase chain reaction for bacteria. Serotypes, resistance genotypes, sequence types and susceptibilities to 14 antimicrobial agents were determined for pneumococcal isolates. Results: At least 1 bacterial pathogen was identified in 473 of the samples (81.3%). Nontypeable Haemophilus influenzae (54.8%) was detected most frequently, followed by Streptococcus pneumoniae (25.4%), Streptococcus pyogenes (2.9%) and others. Pneumococci of current vaccine serotypes have decreased dramatically from 82.1% in 2006 to 18.5% (P < 0.001). Commonest serotypes were 15A (14.8%), 3 (13.9%) and 35B (11.1%). Serotype 3 was significantly less frequent among children receiving 13-valent pneumococcal conjugate vaccine compared with 7-valent pneumococcal conjugate vaccine (P = 0.002). Genotypic penicillin-resistant S. pneumoniae accounted for 28.7%, slightly less than in 2006 (34.2%; P = 0.393); the penicillin-resistant serotypes 15A and 35B had increased. Serotypes 15A, 3 and 35B most often belonged to sequence types 63, 180 and 558. Conclusions: Our findings are expected to assist in development of future vaccines, and they underscore the need for appropriate clinical choice of oral agents based on testing of causative pathogens.
引用
收藏
页码:598 / 604
页数:7
相关论文
共 50 条
  • [41] Pneumococcal Conjugate Vaccine-elicited Antibody Persistence and Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Children Previously Vaccinated with 4 Doses of Either 7-Valent or 13-Valent Pneumococcal Conjugate Vaccine
    Quinet, Beatrice
    Laudat, France
    Gurtman, Alejandra
    Patterson, Scott
    Sidhu, Mohinder
    Gruber, William C.
    Scott, Daniel A.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (10) : 1065 - 1076
  • [42] Use of the 13-valent pneumococcal conjugate vaccine in infants and young children
    Principi, Nicola
    Esposito, Susanna
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 641 - 648
  • [43] Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia
    Urbancikova, Ingrid
    Prymula, Roman
    Goldblatt, David
    Roalfe, Lucy
    Prymulova, Karolina
    Kosina, Pavel
    VACCINE, 2017, 35 (38) : 5186 - 5193
  • [44] Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era
    Olarte, Liset
    Barson, William J.
    Barson, Ryan M.
    Romero, Jose R.
    Bradley, John S.
    Tan, Tina Q.
    Givner, Laurence B.
    Hoffman, Jill A.
    Lin, Philana Ling
    Hulten, Kristina G.
    Mason, Edward O.
    Kaplan, Sheldon L.
    CLINICAL INFECTIOUS DISEASES, 2017, 64 (12) : 1699 - 1704
  • [45] BURDEN OF PNEUMONIA AFTER IMPLEMENTATION OF 13-VALENT CONJUGATE PNEUMOCOCCAL VACCINE
    Strachan, R.
    RESPIROLOGY, 2019, 24 : 99 - 99
  • [46] Invasive Pneumococcal Disease After Implementation of 13-Valent Conjugate Vaccine
    Tam, Pui-Ying Iroh
    Madoff, Lawrence C.
    Coombes, Brandon
    Pelton, Stephen I.
    PEDIATRICS, 2014, 134 (02) : 210 - 217
  • [47] 13-valent pneumococcal conjugate vaccine (PCV13)
    Jefferies, Johanna M. C.
    Macdonald, Emily
    Faust, Saul N.
    Clarke, Stuart C.
    HUMAN VACCINES, 2011, 7 (10): : 1012 - 1018
  • [48] Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine
    Sucher, Allana J.
    Chahine, Elias B.
    Nelson, Michael
    Sucher, Brandon J.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (12) : 1516 - 1524
  • [49] Occult bacteremia etiology following the introduction of 13-valent pneumococcal conjugate vaccine: a multicenter study in Spain
    Susanna Hernández-Bou
    Borja Gómez
    Santiago Mintegi
    Juan J. García-García
    European Journal of Clinical Microbiology & Infectious Diseases, 2018, 37 : 1449 - 1455
  • [50] Changes in Invasive Pneumococcal Disease Spectrum After 13-Valent Pneumococcal Conjugate Vaccine Implementation
    Levy, Corinne
    Varon, Emmanuelle
    Ouldali, Naim
    Bechet, Stephane
    Bonacorsi, Stephane
    Cohen, Robert
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (03) : 446 - 454